Standard doses of glucosamine chondroitin do not appear to raise blood sugar in most people. Clinical trials lasting up to three years, including participants with type 2 diabetes, have found no significant increase in fasting blood glucose. However, there is a small caveat for people who already have impaired glucose tolerance, where some evidence suggests a modest effect worth understanding.
What Clinical Trials Actually Show
The most reassuring evidence comes from long-term studies. In trials lasting up to three years, glucosamine at the typical 1,500 mg daily dose produced no significant change in fasting blood glucose in any group tested: healthy people, those with diabetes, or those with prediabetes. A comprehensive review published in Diabetes/Metabolism Research and Reviews concluded that glucosamine “has no effect on fasting blood glucose levels, glucose metabolism, or insulin sensitivity at any oral dose level” across all these populations.
Even at doses well above what most people take, the effect was absent. When researchers gave healthy subjects 3,000 mg or 6,000 mg of glucosamine in a single sitting (two to four times the standard daily dose), neither plasma glucose nor insulin levels budged.
A study of overweight and obese middle-aged women tracked over 6.5 years found no effect of glucosamine sulfate on HbA1c (a measure of average blood sugar over roughly three months), no increase in the likelihood of developing a high HbA1c level, and no increase in new cases of diabetes. This held true even among participants who started with elevated HbA1c levels, though that subgroup did show slightly higher (but still not statistically significant) odds ratios, suggesting they may warrant closer monitoring.
The Exception: People With Impaired Glucose Tolerance
One small but notable study from Tufts University tested glucosamine sulfate during an oral glucose tolerance test in people with osteoarthritis. Among 13 participants with normal blood sugar, taking glucosamine alongside the glucose drink raised the average glucose response modestly (39 vs. 29 mg·min/ml), but this difference was not statistically significant.
Three participants, however, turned out to have previously undiagnosed glucose tolerance problems. In that small group, glucosamine did produce a statistically significant increase in glucose levels during the test (191 vs. 145 mg·min/ml, p = 0.04). Notably, glucosamine did not change insulin levels in any of the participants, including the two with undiagnosed diabetes. This suggests the supplement wasn’t causing the pancreas to malfunction but may have been interfering with how efficiently the body handles incoming sugar in people whose glucose processing is already compromised.
The study was small, and three participants is not enough to draw firm conclusions. But it does point to a pattern: if your blood sugar regulation is already impaired, you may be more sensitive to glucosamine’s effects than someone with normal metabolism.
Why the Concern Exists in the First Place
The worry about glucosamine and blood sugar comes from real biology, just at a different scale than what oral supplements deliver. Inside your cells, a small fraction of glucose gets diverted into something called the hexosamine biosynthetic pathway. This pathway converts a sugar molecule into a compound that acts as a nutrient sensor, essentially telling the cell, “there’s plenty of fuel available.” When this pathway is overactive, it can modify key proteins involved in insulin signaling, including the receptors that help cells absorb sugar from the blood and the transporter proteins that move sugar inside cells.
Glucosamine enters this same pathway, and in lab studies where it’s infused directly into the bloodstream at high concentrations, it reliably causes insulin resistance. This is why researchers initially raised the alarm. But oral supplements are a very different story. When you swallow a glucosamine capsule, your gut and liver metabolize much of it before it ever reaches your bloodstream in significant amounts. The concentrations that cause problems in IV infusion studies simply aren’t achieved through oral dosing.
What About Chondroitin?
Chondroitin sulfate, the other half of most combination supplements, has a different metabolic profile than glucosamine. It is not known to feed into the hexosamine pathway the way glucosamine does. Animal research has actually pointed in the opposite direction: chondroitin sulfate has shown blood sugar-lowering effects in diabetic animal models and may improve insulin sensitivity. While these findings come from animal studies and can’t be directly applied to humans, they suggest chondroitin is unlikely to be the component that would cause blood sugar problems in a combination supplement.
Practical Guidance for People With Diabetes
The American Diabetes Association’s Standards of Care does not single out glucosamine as a risk but broadly advises that supplements are “not proven as an effective option for lowering your blood glucose or supporting diabetes management.” The ADA also warns that some supplement ingredients can interact with diabetes medications, potentially pushing blood sugar too high or too low. This general caution applies to glucosamine chondroitin as well.
If you have well-controlled type 2 diabetes or prediabetes and want to try glucosamine chondroitin for joint pain, the clinical evidence suggests that standard doses (1,500 mg of glucosamine per day) are unlikely to meaningfully raise your blood sugar. That said, checking your blood sugar more frequently during the first few weeks of supplementation is a reasonable precaution, especially if your glucose control is borderline. If your readings remain stable, the available evidence suggests they will stay that way over the long term.
For people with normal blood sugar, the evidence is clear: glucosamine chondroitin at standard or even elevated doses does not affect glucose metabolism.